Upstream Bio, Inc. Common Stock (UPB)

Price$8.08

Value ScoreD

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-82.44%

Price vs S&P 500 (4W)-16.04%

VGM Score48.86

Market Capitalization$434.39M

All Metrics

Book Value / Share (Quarterly)$5.59

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)33.04%

Cash Flow / Share (Quarterly)$-2.57

Price vs S&P 500 (YTD)-80.14%

Net Profit Margin (TTM)-4718.96%

EPS (TTM)$-2.90

10-Day Avg Trading Volume0.59M

EPS Excl Extra (TTM)$-2.90

EPS (Annual)$-2.66

ROI (Annual)-42.22%

Cash / Share (Quarterly)$5.41

Revenue Growth QoQ (YoY)82.69%

ROA (Last FY)-40.55%

Revenue Growth TTM (YoY)13.15%

EBITD / Share (TTM)$-3.18

Operating Margin (TTM)-5176.49%

Cash Flow / Share (Annual)$-2.46

P/B Ratio1.43x

P/B Ratio (Quarterly)1.61x

Net Income / Employee (Annual)$-1,912,600

EV / Revenue (TTM)101.65x

ROA (TTM)-42.27%

EPS Incl Extra (Annual)$-2.66

Current Ratio (Annual)26.15x

Quick Ratio (Quarterly)22.97x

3-Month Avg Trading Volume1.06M

52-Week Price Return-10.59%

Revenue / Employee (TTM)$44,300

P/S Ratio (Annual)152.21x

Asset Turnover (Annual)0.01x

52-Week High$33.68

EPS Excl Extra (Annual)$-2.66

26-Week Price Return-66.51%

Quick Ratio (Annual)26.02x

13-Week Price Return5.82%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)23.14x

Enterprise Value$337.67M

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$38,100

Pretax Margin (Annual)-5026.03%

Cash / Share (Annual)$6.30

3-Month Return Std Dev67.98%

Net Income / Employee (TTM)$-2,090,200

ROE (Last FY)-42.22%

EPS Basic Excl Extra (Annual)$-2.66

Receivables Turnover (TTM)4.15x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.90

Receivables Turnover (Annual)4.46x

ROI (TTM)-43.82%

P/S Ratio (TTM)130.76x

Revenue / Share (Annual)$0.05

Price vs S&P 500 (52W)-38.79%

Year-to-Date Return-69.21%

5-Day Price Return-0.12%

EPS Normalized (Annual)$-2.66

Net Profit Margin (Annual)-5026.03%

Month-to-Date Return-8.93%

EBITD / Share (Annual)$-2.97

Operating Margin (Annual)-5618.82%

EPS Basic Excl Extra (TTM)$-2.90

P/B Ratio (Annual)4.32x

Pretax Margin (TTM)-4718.96%

Book Value / Share (Annual)$6.26

Price vs S&P 500 (13W)-3.92%

Beta1.15x

Revenue / Share (TTM)$0.06

ROE (TTM)-43.82%

52-Week Low$7.25

vGradeD

gGradeB

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.75est. -0.78

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.08

4.00

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
UPBUpstream Bio, Inc. Common Stock	D	B	C	$8.08
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Upstream Bio is a clinical-stage biotechnology company developing verekitug, a TSLP receptor antagonist for inflammatory diseases. The company is initially targeting severe respiratory disorders where TSLP is a validated pathological driver. This upstream target addresses multiple immune-mediated disease indications.